p38α-selective mitogen-activated protein kinase inhibitor SD-282 reduces inflammation in a subchronic model of tobacco smoke-induced airway inflammation

Journal of Pharmacology and Experimental Therapeutics

Volumn 324, Issue 3, 2008, Pages 921-929

  Medicherla, Satyanarayana ^a,c   Fitzgerald, Mary F ^b   Spicer, Dianne ^b   Woodman, Paul ^b   Ma, Jing Y ^a   Kapoun, Ann M ^a   Chakravarty, Sarvajit ^a   Dugar, Sundeep ^a   Protter, Andrew A ^a   Higgins, Linda S ^a  

^a SCIOS INC   (United States)

^b Argenta Discovery Ltd   (United Kingdom)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; DEXAMETHASONE; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; SD 282; TOBACCO SMOKE; UNCLASSIFIED DRUG; INDOLE 5 CARBOXAMIDE; INDOLE DERIVATIVE; INDOLE-5-CARBOXAMIDE;

AIRWAY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG MEGADOSE; EPITHELIUM CELL; FEMALE; HISTOLOGY; LOW DRUG DOSE; LUNG LAVAGE; LUNG PARENCHYMA; MACROPHAGE; MOUSE; NEUTROPHIL; NEUTROPHILIA; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPARATIVE STUDY; DISEASE MODEL; DRUG ANTAGONISM; ENZYMOLOGY; METABOLISM; SMOKE; SMOKING; TOBACCO;

ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; INDOLES; MICE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PNEUMONIA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKE; SMOKING; TOBACCO;

EID: 40849119969     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.127092     Document Type: Article

References (41)

1. Arcaroli J, Yun HK, Kupfner J, Park JS, Yang KY, and Abraham E (2001) Role of p38 MAP kinase in the development of acute lung injury. Clin Immunol 101:211-219.
2. Badger AM, Bradbeer JN, and Votta B (1996) Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther 279:1453-1461.
3. Barnes PJ (2005a) Emerging targets for COPD therapy. Curr Drug Targets Inflamm Allergy 4:675-683.
4. Barnes PJ (2005b) Targeting histone deacetylase 2 in chronic obstructive pulmonary disease treatment. Expert Opin Ther Targets 9:1111-1121.
5. Birrell MA, Wong S, Hele DJ, McCluskie K, Hardaker E, and Belvisi MG (2005) Related articles. Steroid-resistant inflammation in a rat model of chronic obstructive pulmonary disease is associated with a lack of nuclear factor-κB pathway activation. Am J Respir Crit Care Med 172:74-84.
6. Chialda L, Zhang M, Brune K, and Pahl A (2005) Inhibitors of mitogen-activated protein kinases differentially regulate costimulated T cell cytokine production of mouse airway eosinophilia. Respir Res 6:36.
7. Cox G (1995) Glucocorticoid treatment inhibits apoptosis in human neutrophils: separation of survival and activation outcomes. J Immunol 154:4719-4725.
8. Culpitt SV, Rogers DF, Shah P, De Matos C, Russell RE, Donnelly LE, and Barnes PJ (2003) Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 167:24-31.
9. Eisner MD, Balmes JR, Yelin EH, Katz PP, Hammond SK, Benowitz N, and Blanc PD (2006) Directly measured secondhand smoke exposure and COPD health outcomes. BMC Pulm Med 6:12-18.
10. Fan Chung KF (2006) Phosphodiesterase inhibitors in airways disease. Eur J Pharmacol 533:110-117.
11. Fitzgerald MF, Spicer DJY, Ma JY, Kapoun AM, Kerr I, Almirez R, Connell MO, Lam A, Woodman P, Luedtke G, et al. (2006) Efficacy of the p38 MAP Kinase Inhibitor, SD-282, in an Inflammatory Model of COPD in A/J Mice. Am J Respir Crit Care Med 3:A850.
12. Gan WQ, Man SF, and Sin DD (2005) Effects of inhaled corticosteroids on sputum cell counts in stable chronic obstructive pulmonary disease: a systematic review and a meta-analysis. BMC Pulm Med 5:3-8.
13. G izycki MJ, Hattotuwa KL, Barnes N, and Jeffery PK (2002) Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue. Thorax 57:799-803.
14. Grootendorst DC, Gauw SA, Sterk PJ, Bethke TD, Hospers JJ, Hiemstra PS, and Rabe KF (2005) Treatment with pde4 inhibitor roflumilast reduces sputum neutrophil and eosinophil numbers in patients with COPD. Am J Respir Crit Care Med 10:A543.
15. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, and Mannino DM (2006) Global burden of COPD: systematic review and meta-analysis. Eur Respir J 28:523-532.
16. Hautamaki RD, Kobayashi DK, Senior RM, and Shapiro SD (1997) Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science 277:2002-2004.
17. Highland KB (2004) Inhaled corticosteroids in chronic obstructive pulmonary disease: is there a long-term benefit? Curr Opin Pulm Med 10:113-119.
18. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, et al. (2004) The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 350:2645-2653.
19. Kapoun AM, Gaspar NJ, Wang Y, Damm D, Liu YW, O'Young G, Quon D, Lam A, Munson K, Tran TT, et al. (2006) Transforming growth factor-β receptor type 1 (TGFβRI) kinase activity bunt p38 activation is required for TGFβRI-induced myofibroblast differentiation and profibrotic gene expression. Mol Pharmacol 70:518-531.
20. Leclerc O, Lagente V, Planquois JM, Berthelier C, Artola M, Eichholtz T, Bertrand CP, and Schmidlin F (2006) Involvement of MMP-12 and phosphodiesterase type 4 in cigarette smoke-induced inflammation in mice. Eur Respir J 27:1102-1109.
21. Lee JC, Laydon JT, and McDonnell PC (1994) A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372:739-746.
22. Lim MY, Wang H, Kapoun AM, O'Connell M, O'Young G, Brauer HA, Luedtke GR, Chakravarty S, Dugar S, Schreiner GS, et al. (2004) p38 inhibition attenuates the pro-inflammatory response to C-reactive protein by human peripheral blood mononuclear cells. J Mol Cell Cardiol 37:1111-1114.
23. Loppow D, Schleiss MB, Kanniess F, Taube C, Jorres RA, and Magnussen H (2001) In patients with chronic bronchitis a four week trial with inhaled steroid does not attenuate airway inflammation. Respir Med 95:115-121.
24. Lundbäck B, Lindberg A, Lindstrom M, Ronmark E, Jonsson AC, Jonsson E, Larsson LG, Andersson S, Sandstrom T, and Larsson K (2003) Obstructive lung disease in northern Sweden studies. Not 15 but 50% of smokers develop COPD?-Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med 97:115-122.
25. Ma K, Mallidis C, Bhasin S, Mahabadi V, Artaza J, Gonzalez-Cadavid N, Arias J, and Salehian B (2003) Glucocorticoid-induced skeletal muscle atrophy is associated with up-regulation of myostatin gene expression. Am J Physiol Endocrinol Metab 285:E363-E371.
26. Martorana PA, Beume R, Lucattelli M, Wollin L, and Lungarella G (2005) Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke. Am J Respir Crit Care Med 172:848-853.
27. Meagher LC, Cousin JM, and Seckl JR (1996) Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes. J Immunol 156:4422-4428.
28. Medicherla S, Ma JY, Mangadu R, Jiang Y, Zhao JJ, Almirez R, Kerr I, Stebbins EG, O'Young G, Kapoun AM, et al. (2006a) A selective p38alpha mitogen-activated protein kinase inhibitor reverses cartilage and bone destruction in mice with collagen induced arthritis. J Pharmacol Exp Ther 318:132-141.
29. Medicherla S, Protter AA, Ma JY, Mangadu R, Almirez R, Koppelman B, Kerr I, Navas TA, Movius F, Reddy M, et al. (2006b) Preventive and therapeutic potential of p38α selective mitogen activated protein kinase inhibitor in nonobese diabetic mice with type-1 diabetes. J Pharmacol Exp Ther 318:99-107.
30. Nath P, Leung SY, Williams A, Noble A, Chakravarty SD, Luedtke GR, Medicherla S, Higgins LS, Protter A, and Chung KF (2006) Importance of p38 mitogen-activated protein kinase pathway in allergic airway remodeling and bronchial hyperresponsiveness. Eur J Pharmacol 544:160-167.
31. New L and Han J (1988) The p38 MAP kinase pathway and its biological function. Trends Cardiovasc Med 8:220-228.
32. O'byrne PM and Postma DS (1999) The many faces of airway inflammation: asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 159:S41-S66.
33. Saetta M (1999) Airway inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 160:S17-S20.
34. Saetta M, Turato G, Maestrelli P, Mapp CE, and Fabbri LM (2001) Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 163:1304-1309.
35. Sweitzer SM, Medicherla S, Almirez R, Dugar S, Chakravarty S, Shumilla JA, Yeomans DC, and Protter AA (2004) Antinociceptive action of a p38α MAPK inhibitor, SD-282, in a diabetic neuropathy model. Pain 109:409-419.
36. Sutherland ER and Cherniack RM (2004) Current concepts: management of chronic obstructive pulmonary disease. New Engl J Med 350:2689-2697.
37. Tigani B, Di Padova F, Zurbrugg S, Schaeublin E, Revesz L, Fozard JR, and Beckmann N (2003) Effects of mitogen-activated protein kinase inhibitor on allergic airways inflammation in the rat studied by magnetic resonance imaging. Eur J Pharmacol 15:319-324.
38. Tsai JR, Chong IW, Chen CC, Lin SR, Sheu CC, and Hwang JJ (2006) Mitogen-activated protein kinase pathway was significantly activated in human bronchial epithelial cells by nicotine. DNA Cell Biol 25:312-322.
39. Turato G, Zuin R, Miniati M, Baraldo S, Rea F, Beghe B, Monti S, Formichi B, Boschetto P, Harari S, et al. (2002) Airway inflammation in severe chronic obstructive pulmonary disease: relationship with lung function and radiologic emphysema. Am J Respir Crit Care Med 166:105-110.
40. Xu GL, Yao L, Rao SY, Gong ZN, Zhang SQ, and Yu SQ (2005) Attenuation of acute lung injury in mice by oxymatrine is associated with inhibition of phosphorylated p38 mitogen-activated protein kinase. J Ethnopharmacol 98:177-183.
41. Zhang X, Moilanen E, and Kankaranta H (2001) Beclomethasone, budesonide and fluticasone propionate inhibit human neutrophil apoptosis. Eur J Pharmacol 431:365-371.